Medi Futures, a Seoul South Korea based Biomedical ultrasound company has now secured $5 Million in the funding round with the help of some of the common tasks.
The investment came from the Korean investors such as the ST Capital and Samho Green Investments and strategic investors from China and US. The investment is also expected to accelerate the CFDA and FDA approvals.
Medi Futures has come up with the more commercialized ultrasonic endoscopic disk surgical instruments and enzyme-free ultrasound stem cell separators which are based on the ultrasonic platform technology. As of now, the company has developed and exported medical sutures with the high precision anchoring points.
Medi is a member company of the K-ICT Born2Global Venter and recently participated in a training program which is going to be held at Medtronic Asia Pacific Headquarters.
CEO Kim Ji-Min of MEDI FUTURES revealed in a statement, “It is going to be much more meaningful than this investment comes 100% in the form of common stocks with the help of strategic partnerships, rather than through some of the simpler financial investment. This investment is expected to accelerate with the approvals from the FDA and CFDA. Moving forward, we will soon also be going to continue to strengthen our strategy of global advancement to become the world's number one company in our domain in the market.”
CEO Jo Soo-Bong of Samho Green Investment revealed that, “The sales volumes of MEDI FUTURES' medical devices which are as of now currently stand at almost US$30B and continue to grow at an annual rate of 12%. The devices are part of some of the minimally invasive medical field that is expanding across the globe. The pros of these devices are that they minimize tissue damage and help patients to recover with some of the more quickly and instantly. Given, that more than 80% of the company's sales come from markets which is overseas, the company is highly expected to continue to grow in the coming months as well.”
You may also like to read: